Bilateral carotid-jugular arteriovenous graft implantation in an ovine model is safe and durable for facilitation of arteriovenous graft innovation

Abstract

Over 550 000 people in the U.S. require hemodialysis for management of end stage renal disease (ESRD). When anatomy restricts fistula creation, arteriovenous grafts (AVG) are implanted. AVGs have poor primary patency and high risk of infection, highlighting a need for better alternatives. Previous AVG large animal models were limited by high complication rates and short-term follow-up. This study investigates the safety and durability of an ovine bilateral carotid-jugular AVG model. Eight female sheep underwent bilateral carotid-jugular AVG implantation via a single longitudinal incision overlying the trachea. Ringed PTFE grafts were anastomosed in a “lazy-S” configuration to provide the laxity needed to prevent avulsion and minimize kinking with neck movement. Post-operatively, sheep were evaluated daily to monitor for complications. Duplex ultrasonography of the grafts was performed at regular intervals out to 6 months to evaluate patency. At 6 months, angiography and duplex was performed followed by explant for gross and histologic analysis. Technical success was achieved in 16 of 16 (100%) graft implants. No major complications, including stroke, anastomotic disruption, infection, wound breakdown, or death occurred. Primary patency of control PTFE grafts was 75% at 6 months, paralleling reported rates in humans. Bilateral carotid-jugular AVG implantation in sheep is a safe and durable model for self-controlled long-term evaluation of AVG conduit technology.

Keywords

Animal / Biomedical / Models / Polytetrafluoroethylene / Renal Dialysis / Sheep / Translational Research / Vascular Patency

References

[1] National Institutes of Health (NIH). National Institute of Diabetes and Digestive and Kidney Diseases: 2024 Annual Report. End Stage Renal Disease: Chapter 1 Incidence, Prevalence, Patient Characteristics, and Treatment Modalities. https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/1-incidence-prevalence-patient-characteristics-and-treatment-modalities

[2] Al-Jaishi AA, Oliver MJ, Thomas SM, et al. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63(3):464-478.

[3] Voorzaat BM, Janmaat CJ, van der Bogt KEA, Dekker FW, Rotmans JI. Patency outcomes of arteriovenous fistulas and grafts for hemodialysis access: a trade-off between nonmaturation and Long-term complications. Kidney360. 2020;1(9):916-924.

[4] Levin SR, Farber A, Cheng TW, et al. Risk assessment of significant upper extremity arteriovenous graft infection in the vascular quality initiative. J Vasc Surg. 2020;71(3):913-919.

[5] Zarrintan S, Sim DJK, Hamouda M, Malas M, Ross E. Reintervention rates and costs following dialysis access placement: insights from the vascular quality initiative database. J Vasc Surg. 2025;81(6):e70.

[6] Schleimer K, Jalaie H, Afify M, et al. Sheep models for evaluation of novel patch and prosthesis material in vascular surgery: tips and tricks to avoid possible pitfalls. Acta Vet Scand. 2018;60(1):42.

[7] Rashid ST, Salacinski HJ, Hamilton G, Seifalian AM. The use of animal models in developing the discipline of cardiovascular tissue engineering: a review. Biomaterials. 2004;25(9):1627-1637.

[8] Fitts MK, Pike DB, Anderson K, Shiu YT. Hemodynamic shear stress and endothelial dysfunction in hemodialysis access. Open Urol Nephrol J. 2014;7(Suppl 1 M5):33-44.

[9] Byrom MJ, Bannon PG, White GH, Ng MKC. Animal models for the assessment of novel vascular conduits. J Vasc Surg. 2010;52(1):176-195.

[10] Pennel T, Bezuidenhout D, Koehne J, Davies NH, Zilla P. Transmural capillary ingrowth is essential for confluent vascular graft healing. Acta Biomater. 2018;65:237-247.

[11] Zilla P, Von Oppell U, Deutsch M. The endothelium: a key to the future. J Card Surg. 1993;8(1):32-60.

[12] Allen BT, Long JA, Clark RE, Sicard GA, Hopkins KT, Welch MJ. Influence of endothelial cell seeding on platelet deposition and patency in small-diameter Dacron arterial grafts. J Vasc Surg. 1984;1(1):224-233.

[13] Zhuang Y, Zhang C, Cheng M, et al. Challenges and strategies for in situ endothelialization and long-term lumen patency of vascular grafts. Bioact Mater. 2021;6(6):1791-1809.

[14] Ong CS, Fukunishi T, Liu RH, et al. Bilateral arteriovenous shunts as a method for evaluating tissue-engineered vascular grafts in large animal models. Tissue Eng Part C Methods. 2017;23(11):728-735.

[15] Halbert RJ, Nicholson G, Nordyke RJ, Pilgrim A, Niklason L. Patency of ePTFE arteriovenous graft placements in hemodialysis patients: systematic literature review and meta-analysis. Kidney360. 2020;1(12):1437-1446.

[16] Huber TS, Carter JW, Carter RL, Seeger JM. Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg. 2003;38(5):1005-1011.

[17] Zilla P, Bezuidenhout D, Human P. Prosthetic vascular grafts: wrong models, wrong questions and no healing. Biomaterials. 2007;28(34):5009-5027.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.